The major plan by Japan-based pharmaceutical giant Hisamitsu Pharmaceutical Co. to go private in a deal worth 457 billion yen (approximately $2.9 billion) is seen as a prime example of a "flight from public markets" by a star Japanese drugmaker. Stock market analysts in Japan anticipate more companies will follow suit, potentially triggering an unprecedented wave of privatization deals in the Japanese pharmaceutical sector in the near future. This expectation is a key reason behind the recent sharp stock price increases for undervalued Japanese pharmaceutical companies, as investors widely bet that a privatization trend will sweep through listed drug firms in Japan. Under the dual pressures of intense scrutiny from short-term investors and government-mandated price cuts, some small and mid-sized pharma firms, and even certain larger, top-tier Japanese drugmakers, are opting to delist to seek greater management flexibility. This move allows them to implement significant cost reductions, reshape their product portfolios, and aggressively pursue long-term investments. Over the past two years, established Japanese pharma giants Mitsubishi Tanabe Pharma Corp. and Taisho Pharmaceutical Holdings Co. have already been successfully taken private; meanwhile, activist investor Dalton Investments LLC has urged Aska Pharmaceutical Holdings Co. to consider a similar privatization move.

Hisamitsu's plan, led by CEO Kazuhiko Nakafuji—an important member of the company's founding family—ranks as one of the largest privatization transactions ever in Japan's pharmaceutical sector and has propelled the company's stock price to a staggering 38% surge over just two trading days. Senior analysts Stephen Barker and Miyabi Yamakita from Wall Street giant Jefferies' Japan unit, Jefferies Japan Ltd., stated that investors will be paying closer attention to Japanese healthcare stocks trading at low valuation multiples. "Hisamitsu's major move may not be an isolated case, but rather part of a broader privatization trend within Japan's pharmaceutical industry," they wrote in a recent client disclosure report. The two analysts found that among the major Japanese pharmaceutical companies they studied, 12 listed firms—about one-third—currently trade at a price-to-book ratio below 1, indicating that parts of the sector are severely undervalued by investors and presenting a ripe opportunity for privatization-seeking capital. They highlighted that potential acquisition targets include attractively valued Kissei Pharmaceutical Co., as well as Kyowa Kirin Co. Ltd. and Sumitomo Pharma Co., which possess privatization potential due to their parent companies' shareholding structures.

Notably, the number of listed companies on the Tokyo Stock Exchange declined for the first time in over a decade, primarily due to privatizations and a record number of delistings related to restructuring pressures from exchange reforms. On Thursday, the market appeared to be betting on the imminent arrival of a privatization wave in Japan's pharma sector, with Hisamitsu's stock rising as much as 8% intraday, bringing its cumulative gain over the two sessions since the news broke to a remarkable 38%. Also on Thursday, Sumitomo Pharma's shares jumped as much as 12%, marking their largest intraday gain since November. Kyowa Kirin rose about 1.8% at one point, while Kissei's stock climbed up to 2.8%, hitting its highest level in seven weeks.

With the Bank of Japan embarking on an interest rate hiking cycle, benchmark rates are set to continue rising, significantly increasing borrowing costs. Hiroshi Nakamura, Dean of Keio University Business School, stated in an interview that the cost of privatization will be higher in the future if investors and pharmaceutical companies delay decisions on financing such deals. "Timing-wise, the sooner for privatization, the better," Nakamura said. "But a privatization buyout is a method, not an ultimate solution; if they lack a clear strategy for the next steps, they will likely fail in the end." Japan's pharmaceutical industry is currently under particular investor scrutiny, mainly because drugmakers face significant pressure from policy changes. The Japanese government has been pushing for lower prescription drug prices and promoting a cheaper generic drug system to control costs and sustain its universal health insurance system amid an aging population, thereby squeezing profits across the entire pharmaceutical sector. According to documents from Japan's Ministry of Health, Labour and Welfare, starting from the new fiscal year in April, patients will bear higher out-of-pocket costs for certain brand-name drugs and drugs equivalent to over-the-counter medications.

To revitalize performance and market share growth amid intensifying domestic competition, Hisamitsu is accelerating its overseas expansion. The company stated that its strategic focus is on maximizing the value of its prescription drugs while simultaneously developing new products using microneedle technology—a method that enables faster, more efficient, and more user-friendly drug delivery. It is also reorganizing its over-the-counter drug business and e-commerce sales operations, Hisamitsu said in a disclosure statement on Tuesday.

"Privatization will certainly continue to occur in the small and mid-sized enterprise space, but it is also highly likely to happen among larger market capitalization pharmaceutical companies," said Patrick Branch, a partner at L.E.K. Consulting. However, he added, "Privatization is not the ultimate solution to problems. Some listed companies are not on the right operational path, lack suitable management, or do not have the substantial capital required for a complete turnaround."

Against the backdrop of ongoing policy pressures squeezing pharmaceutical profits—driven by the Japanese government's push for drug price cuts and promotion of generics—the "short-term performance pressure" from public markets persistently conflicts with the need for transformation. Amid changing drug pricing and demand structures, companies often need to undertake more aggressive cost restructuring, make portfolio/pipeline choices, pursue overseas expansion, and invest in new technologies; these actions can hurt profits and Return on Equity (ROE) in the short term,更容易与公开市场的季度考核发生冲突, thereby increasing the attractiveness of "undertaking long-cycle transformations after delisting." Under Japan's healthcare cost-containment framework, the government has an institutional mechanism for regularly lowering National Health Insurance (NHI) drug prices, coupled with policy directives favoring generics and lower-cost alternatives, which inherently pressures industry profit margins. This is particularly evident for companies focused primarily on the domestic Japanese prescription drug/OTC market and those with less efficient R&D. Furthermore, Hisamitsu's Management Buyout (MBO) offer, representing a roughly 35% premium to the previous closing price, sends a very clear positive signal to the market: there exists a compelling narrative path for undervalued, well-known Japanese pharma firms to achieve value re-rating through M&A/privatization. Consequently, this is naturally expected to stimulate global capital and M&A advisors to screen the Japanese stock market for the next batch of "replicable pharmaceutical targets."

Privatization/delisting transactions in Japan have increased significantly in recent years, with private equity and industrial capital more willing to intervene via "restructuring + operational improvement" strategies; the acquisition of Mitsubishi Tanabe by Bain Capital is a classic case study. Simultaneously, the shareholding structures of some listed subsidiaries/parent companies make "parent company buybacks and intra-group integration" smoother to execute. Regarding monetary policy expectations, as Japan moves into a new interest rate hiking cycle and financing costs rise (the Bank of Japan has already raised its policy rate to 0.75% and signalled a tendency for further hikes), this will incentivize companies and financial investors to complete financing and transaction arrangements before costs climb further, thereby accelerating the pace of pharmaceutical company privatizations.